Humulin Regular (Dialytí) Kwikpen

Humulin Regular (Dialytí) Kwikpen is a pre‑filled insulin pen that delivers insulin human (recombinant DNA) as an injectable solution. It contains regular insulin (100 U/mL) for subcutaneous administration. The product is authorized in the European Union and is prescribed by professionals for the management of diabetes mellitus. It provides a rapid onset of action, beginning within 30 minutes after injection, and is used in basal‑bolus insulin regimens.

Humulin Regular Kwikpen is indicated for the control of blood glucose in patients with diabetes requiring short‑acting insulin therapy.

- Type 1 diabetes mellitus as part of a basal‑bolus regimen. - Type 2 diabetes mellitus when rapid glucose reduction is needed. - Management of hyperglycemia during illness, surgery, or steroid therapy. - Use in pregnant or lactating women only when benefits outweigh risks (under medical supervision). - Supplemental insulin for patients transitioning from other rapid‑acting insulin preparations. - Adjustment of dose in response to carbohydrate intake and physical activity.

Adverse reactions to Humulin Regular Kwikpen are categorized by frequency and clinical significance.

Common: - Hypoglycemia, presenting as sweating, tremor, dizziness, or hunger. - Redness, swelling, or itching at the injection site. - Lipodystrophy, including localized lipoatrophy or lipohypertrophy. - Gradual weight gain associated with improved glycemic control. - Mild gastrointestinal discomfort such as nausea or abdominal fullness.

Serious: - Severe hypoglycemia leading to confusion, loss of consciousness, or seizures. - Allergic reactions ranging from urticaria and angioedema to anaphylactic shock. - Persistent hyperglycemia suggesting possible insulin resistance or dosing error. - Fluid retention, peripheral edema, or worsening heart failure in at‑risk individuals.

Before initiating therapy with Humulin Regular Kwikpen, clinicians and patients should consider several precautionary measures.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review history of hypoglycemia unawareness or prior severe episodes. - Adjust doses when initiating or discontinuing concomitant glucocorticoids, β‑blockers, or thiazide diuretics. - Monitor blood glucose closely during periods of illness, fasting, or changes in physical activity. - Educate patients on proper injection technique and rotation of sites to reduce lipodystrophy. - Use caution in pregnant or lactating women; benefits must outweigh potential risks. - Consider cardiovascular status, especially in patients with known heart failure.

Humulin Regular Kwikpen can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - High‑dose β‑blockers that may mask hypoglycemia symptoms. - MAO‑A inhibitors combined with sympathomimetic agents, increasing risk of hypertensive crisis.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia. - Corticosteroids, which can raise blood glucose and require insulin dose increase. - Thiazide diuretics and ACE inhibitors, which may affect potassium balance and insulin sensitivity. - Alcohol consumption, especially in excess, which can cause delayed hypoglycemia.